Atrovent and albuterol metered dose inhalers are being taken off the market.

  This confusion stems from promotional ads and drug reps for Spiriva and Xopenex claiming that Atrovent and albuterol inhalers are being discontinued. But they fail to mention that these products will remain commercially available in an HFA formulation.

  Chlorofluorocarbons (CFCs) are in the process of being phased out of inhaler products because of concern that they deplete the Earth's ozone layer.

  Boehringer Ingelheim has already discontinued Atrovent MDIs formulated with CFC propellant. And fewer albuterol CFC inhalers are being made since they are due to be completely withdrawn from the market by December 31, 2008.